Filing Details
- Accession Number:
- 0001384101-21-000180
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-08 16:42:10
- Reporting Period:
- 2021-12-06
- Accepted Time:
- 2021-12-08 16:42:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1384101 | Veracyte Inc. | VCYT | Services-Medical Laboratories (8071) | 205455398 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1769333 | C Giulia Kennedy | 6000 Shoreline Court Suite 300 South San Francisco CA 94080 | Chief Scientific & Med Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-12-06 | 4,406 | $5.98 | 53,394 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-12-06 | 3,750 | $20.21 | 57,144 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-12-06 | 3,550 | $35.37 | 53,594 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-12-06 | 3,897 | $36.11 | 49,697 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-12-06 | 1,785 | $37.26 | 47,912 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-12-07 | 4,375 | $24.69 | 52,287 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-12-07 | 1,750 | $26.55 | 54,037 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-12-07 | 4,375 | $39.69 | 49,662 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-12-07 | 1,750 | $41.55 | 47,912 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-12-06 | 4,406 | $0.00 | 4,406 | $5.98 |
Common Stock | Stock Option (right to buy) | Disposition | 2021-12-06 | 3,750 | $0.00 | 3,750 | $20.21 |
Common Stock | Stock Option (right to buy) | Disposition | 2021-12-07 | 4,375 | $24.69 | 4,375 | $24.69 |
Common Stock | Stock Option (right to buy) | Disposition | 2021-12-07 | 1,750 | $26.55 | 1,750 | $26.55 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
4,407 | 2028-03-01 | No | 4 | M | Direct | |
18,750 | 2029-02-27 | No | 4 | M | Direct | |
39,375 | 2030-03-27 | No | 4 | M | Direct | |
0 | 2030-05-10 | No | 4 | M | Direct |
Footnotes
- The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.
- Represents weighted average sales price. Sale prices for the transactions range from $34.70 to $35.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- Represents weighted average sales price. Sale prices for the transactions range from $35.79 to $36.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- Represents weighted average sales price. Sale prices for the transactions range from $36.88 to $37.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuousservice thereafter.
- The option is fully vested.